Ex-Merck Partner Symphogen Expects €67.5m To Burn A Hole In Its R&D Pocket
This article was originally published in Scrip
Executive Summary
If all goes to plan, Symphogen – the Danish biotechnology company developing antibody mixture therapies to treat cancer – expects to need more cash within a year, despite raising €67.5m via a convertible debt facility from existing investors this week. The round was led by Novo A/S and the Danish pension fund PKA.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.